1 week Ago By ABMN Staff
Strategic Financial Concepts LLC acquired a new stake in Sanofi ( NASDAQ:SNY – Free Report ) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 25,895 shares of the company’s stock, valued at approximately $1,256,000. Other institutional investors also recently bought and sold shares of the company.
Cascade Investment Advisors Inc. increased its stake in Sanofi by 4.7% in the 1st quarter.
Cascade Investment Advisors Inc. now owns 34,359 shares of the company’s stock valued at $1,670,000 after buying an additional 1,535 shares during the period. Vestal Point Capital LP acquired a new position in shares of Sanofi during the 4th quarter worth $14,919,000.
Dynamic Advisor Solutions LLC grew its stake in shares of Sanofi by 39.2% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 57,204 shares of the company’s stock worth $2,780,000 after purchasing an additional 16,117 shares during the period.
Manning & Napier Advisors LLC acquired a new position in shares of Sanofi during the 2nd quarter worth $13,725,000. Finally, Oxbow Advisors LLC acquired a new position in shares of Sanofi during the 4th quarter worth $4,689,000. 10.
04% of the stock is owned by institutional investors and hedge funds. Sanofi Price Performance Sanofi stock opened at $57.73 on Monday.
Sanofi has a 52 week low of $42.63 and a 52 week high of $58.97.
The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.
17. The firm’s 50-day simple moving average is $52.82 and its 200 day simple moving average is $49.
84. The firm has a market capitalization of $146.21 billion, a PE ratio of 29.
01, a P/E/G ratio of 1.64 and a beta of 0.60.
Wall Street Analysts Forecast Growth A number of equities analysts have recently weighed in on the stock. Argus upped their price target on shares of Sanofi from $55.00 to $60.
00 and gave the stock a “buy” rating in a research note on Friday, July 26th. StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 3rd.
Three analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $57.
50. View Our Latest Report on SNY About Sanofi ( Free Report ) Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments.
The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. Further Reading Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi ( NASDAQ:SNY – Free Report ).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter ..
